November 1, 2019
Daiichi Sankyo enjoyed higher profits on higher sales in the first six months of FY2019, buoyed by growth of its major anticoagulant edoxaban and its key global oncology alliance with AstraZeneca, the company said on October 31. In April-September, the...read more